But how much better would our creative be if we took the time to really listen to what our clients are saying – and what they are not saying – rather than reading between the lines of an RFP?
Improving the productivity of sponsors’ clinical development processes will continue to be a primary driver of outsourcing in 2018, writes Nuala Murphy.
Are the technologies and assumptions at the heart of healthcare AI trustworthy?
Both foreign and domestic pharmas are in a race to bring PD-1/PD-L1 inhibitors into China, writes Jin Zhang.
This article examines the key ways the new tax bill will impact the pharmaceutical industry.
Key takeaways on digital health from the 2021 JP Morgan Healthcare conference.
Adhering to new compliance legislation such as Identification of Medicinal Products (IDMP) can bring a pharma company benefits as well as challenges, writes Darren Cooper.
For companies that overcome the challenges, there is tremendous opportunity to drive sustainable growth through technology and analytics-driven business innovation, writes Vita Cassese.
Innovations in consumer genetic health are rapidly advancing-and pharma commercial thinking needs to catch up.
Innovations in consumer genetic health are rapidly advancing-and pharma commercial thinking needs to catch up.
Drawing from implementation lessons and successes in other industries, possible strategy shifts to pharma’s pricing playbook are explored.
Drawing from implementation lessons and successes in other industries, possible strategy shifts to pharma’s pricing playbook are explored.
AdTech (Advertising Technology) and AI/ML (Artificial Intelligence/Machine Learning) are playing significant roles in transforming the healthcare industry, particularly in areas like digital marketing and clinical trials. Let's explore each area in more detail.
Steve Cottrell assesses the risks of lapses in pharma's supply chain visibility and outlines what can be done to minimize them
The biopharma industry should embrace the developments about value assessment in the US and take a leading role in defining and demonstrating what can be considered credible and relevant cost-effectiveness studies, write Ross Maclean and Jeroen Jansen.
Without considering the organizational and talent aspects of change, companies put themselves at risk for poor employee engagement, loss of talent, and ultimately, failed business initiatives, writes Viq Prevaaz.
Three ways AR can bolster pharma commercialization strategies.
COVID-19 has been game-changing for pharma sales, driving demand for new models and reps with the right competencies and skills to succeed in a hybrid sales environment.
Jo Pisani and Cynthia Chan outline the key legal considerations for post-deal integration.
This op-ed discusses the varying skills that business leaders should look at in scientists when thinking about talent for the lab and the executive suite.
In Part 4 of a 4-part series on brand teams, this article discusses the tactics brand teams and partners should follow to improve medication and persistence.